InsiderTradr

Pharming Group N.V. (0QCO.IL)

IOB · EUR · Healthcare · Biotechnology

€1.07 (+0.63%) as of

Key statistics

Market cap
842.05M
EPS (TTM)
-0.0200
52-week range
0.0000 – 1.8270
Beta
0.87
Revenue (TTM)
206.3M
Profit margin
-7.96%

About Pharming Group N.V.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Sector
Healthcare
Industry
Biotechnology
Headquarters
Leiden, Netherlands
Employees
332

pharming.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks